Literature DB >> 28138570

A STORM in a teacup?-the challenges of adjuvant therapy in hepatocellular carcinoma (HCC).

Kirti Shetty1, Aiwu Ruth He2.   

Abstract

Entities:  

Year:  2016        PMID： 28138570      PMCID： PMC5244741          DOI： 10.21037/tgh.2016.03.10

Source DB:  PubMed          Journal:  Transl Gastroenterol Hepatol        ISSN： 2415-1289


× No keyword cloud information.
  11 in total

1.  Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection: a randomized controlled trial.

Authors:  Yong Xia; Yinghe Qiu; Jun Li; Lehua Shi; Kui Wang; Tao Xi; Feng Shen; Zhenlin Yan; Mengchao Wu
Journal:  Ann Surg Oncol       Date:  2010-07-03       Impact factor: 5.344

2.  Multiple courses of immunotherapy with different immune cell types for patients with hepatocellular carcinoma after microwave ablation.

Authors:  Ming-An Yu; Ping Liang; Xiao-Ling Yu; Zhi-Yu Han; Xue-Juan Dong; Y U Wang; Chao Cheng; Xin Li
Journal:  Exp Ther Med       Date:  2015-08-14       Impact factor: 2.447

Review 3.  Molecularly targeted therapies for hepatocellular carcinoma: sorafenib as a stepping stone.

Authors:  Hwi Young Kim; Joong-Won Park
Journal:  Dig Dis       Date:  2011-08-09       Impact factor: 2.404

4.  Angiotensin receptor blockers improve survival outcomes after radiofrequency ablation in hepatocarcinoma patients.

Authors:  Antonio Facciorusso; Valentina Del Prete; Nicola Crucinio; Nicola Muscatiello; Brian I Carr; Alfredo Di Leo; Michele Barone
Journal:  J Gastroenterol Hepatol       Date:  2015-11       Impact factor: 4.029

5.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.

Authors:  Jacques Ferlay; Hai-Rim Shin; Freddie Bray; David Forman; Colin Mathers; Donald Maxwell Parkin
Journal:  Int J Cancer       Date:  2010-12-15       Impact factor: 7.396

Review 6.  Treatment of hepatocellular carcinoma: a systematic review.

Authors:  Shibo Lin; Katrin Hoffmann; Peter Schemmer
Journal:  Liver Cancer       Date:  2012-11       Impact factor: 11.740

7.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.

Authors:  Ann-Lii Cheng; Yoon-Koo Kang; Zhendong Chen; Chao-Jung Tsao; Shukui Qin; Jun Suk Kim; Rongcheng Luo; Jifeng Feng; Shenglong Ye; Tsai-Sheng Yang; Jianming Xu; Yan Sun; Houjie Liang; Jiwei Liu; Jiejun Wang; Won Young Tak; Hongming Pan; Karin Burock; Jessie Zou; Dimitris Voliotis; Zhongzhen Guan
Journal:  Lancet Oncol       Date:  2008-12-16       Impact factor: 41.316

Review 8.  Adjuvant antiviral therapy for hepatitis B virus-related hepatocellular carcinoma after curative treatment: A systematic review and meta-analysis.

Authors:  Gao-Min Liu; Xiao-Yong Huang; Shun-Li Shen; Wen-Jie Hu; Bao-Gang Peng
Journal:  Hepatol Res       Date:  2015-10-06       Impact factor: 4.288

9.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

10.  A phase I/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic cells in patients with hepatocellular carcinoma.

Authors:  Jeong-Hoon Lee; Yoon Lee; Minjong Lee; Min Kyu Heo; Jae-Sung Song; Ki-Hwan Kim; Hyunah Lee; Nam-Joon Yi; Kwang-Woong Lee; Kyung-Suk Suh; Yong-Soo Bae; Yoon Jun Kim
Journal:  Br J Cancer       Date:  2015-12-10       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.